An Observational, Retrospective Analysis of Retreatment with Bortezomib for Multiple Myeloma
Authors:
- QuynhChau D. DoanQDQuynhChau D. Doan
- Ian B. WaltersIWIan B. Walters
- Annette L. LeBlancALAnnette L. LeBlanc
- Roy A. BeveridgeRBRoy A. Beveridge
- 1 June 2008
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 8 (3) , 140-145
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialBlood, 2007
- Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicinAnnals of Hematology, 2006
- Beyond single-agent bortezomib: combination regimens in relapsed multiple myelomaCurrent Opinion in Oncology, 2006
- Epidemiology and outcomes research for MGUS, myeloma and amyloidosisEuropean Journal of Cancer, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- Multiple myelomaThe Lancet, 2004
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003
- The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood, 2003
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998